Loading…
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $194M | $-2M | $14M | $-1M | 62.0% | 25.3% | - |
| 2024 | $155M | $-14M | $-21M | $9M | 283.4% | 1.5% | - |
| 2023 | $153M | $-8M | $-21M | $0M | -370.0% | 28.2% | - |
| 2022 | $119M | $-36M | $-46M | $-36M | 623.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 119.03 | 152.55 | 154.82 | 194.06 |
| Cost Of Revenue | 18.67 | 18.90 | 21.44 | 27.71 |
| Gross Profit | 100.37 | 133.65 | 133.38 | 166.34 |
| Operating Expense | 140.05 | 148.14 | 153.79 | 174.01 |
| Operating Income | -39.69 | -14.49 | -20.40 | -7.67 |
| EBITDA | -35.92 | -7.89 | -14.21 | -1.52 |
| EBIT | -39.69 | -14.49 | -20.40 | -8.83 |
| Pretax Income | -44.66 | -17.41 | -22.58 | -10.19 |
| Tax Provision | 0.36 | 0.43 | 0.60 | 0.05 |
| Net Income | -45.54 | -20.60 | -21.41 | 14.35 |
| Net Income Common Stockholders | -48.64 | -23.70 | -24.52 | 11.25 |
| Total Expenses | 158.72 | 167.04 | 175.23 | 201.72 |
| Interest Expense | 0 | 0 | 2.18 | 1.36 |
| Research And Development | 2.97 | 6.06 | 6.86 | 7.35 |
| Selling General And Administration | 125.33 | 128.15 | 128.05 | 144.01 |
| Normalized EBITDA | -32.22 | -7.56 | -14.21 | -0.36 |
| Normalized Income | -42.61 | -20.34 | -23.72 | -10.58 |
| Basic EPS | -1.57 | -0.70 | -0.53 | 0 |
| Diluted EPS | -1.57 | -0.70 | -0.53 | 0 |
| Tax Effect Of Unusual Items | -0.78 | -0.07 | 0 | -0.24 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -3.70 | -0.33 | 0 | -1.16 |
| Total Unusual Items Excluding Goodwill | -3.70 | -0.33 | 0 | -1.16 |
| Net Income From Continuing Operation Net Minority Interest | -45.54 | -20.60 | -23.72 | -11.50 |
| Reconciled Depreciation | 3.77 | 6.60 | 6.19 | 7.31 |
| Reconciled Cost Of Revenue | 18.67 | 18.90 | 21.44 | 27.71 |
| Net Interest Income | -1.28 | -2.60 | -2.18 | -1.36 |
| Net Income From Continuing And Discontinued Operation | -45.54 | -20.60 | -21.41 | 14.35 |
| Total Operating Income As Reported | -43.45 | -14.49 | -20.40 | -7.67 |
| Diluted Average Shares | 30.98 | 33.91 | 41.20 | 0 |
| Basic Average Shares | 30.98 | 33.91 | 41.20 | 0 |
| Diluted NI Availto Com Stockholders | -48.64 | -23.70 | -24.52 | 11.25 |
| Preferred Stock Dividends | 3.11 | 3.11 | 3.11 | 3.11 |
| Minority Interests | -0.51 | -2.76 | -0.55 | -1.27 |
| Net Income Including Noncontrolling Interests | -45.02 | -17.84 | -20.86 | 15.62 |
| Net Income Discontinuous Operations | 0 | 0 | 2.32 | 25.85 |
| Net Income Continuous Operations | -45.02 | -17.84 | -23.18 | -10.23 |
| Other Income Expense | -3.70 | -0.33 | 0 | -1.16 |
| Special Income Charges | -3.70 | -0.33 | 0 | -1.16 |
| Other Special Charges | -0.06 | 0.33 | 0 | 1.16 |
| Impairment Of Capital Assets | 8.86 | 0 | 0 | 0 |
| Restructuring And Mergern Acquisition | -5.10 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -1.28 | -2.60 | -2.18 | -1.36 |
| Total Other Finance Cost | 1.28 | 2.60 | 2.18 | 0 |
| Interest Expense Non Operating | 0 | 0 | 2.18 | 1.36 |
| Other Operating Expenses | 11.75 | 13.93 | 18.88 | 22.65 |
| Selling And Marketing Expense | 78.37 | 76.45 | 70.10 | 86.07 |
| General And Administrative Expense | 46.96 | 51.69 | 57.95 | 57.94 |
| Other Gand A | 46.96 | 51.69 | 57.95 | 57.94 |
| Operating Revenue | 119.03 | 152.55 | 154.82 | 194.06 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| LifeMD, Inc.this co. | LFMD | $210M | - | 8.93 | 62.0% | -27.13 |
| Voyager Therapeutics, Inc. | VYGR | $220M | - | 1.10 | -61.1% | -0.46 |
| Keros Therapeutics, Inc. | KROS | $220M | 4.83 | 0.72 | 28.7% | -0.72 |
| Sight Sciences, Inc. | SGHT | $216M | - | 3.32 | -60.1% | -4.83 |
| Electromed, Inc. | ELMD | $208M | 24.37 | 4.57 |
| 17.4% |
| 15.06 |
| Utah Medical Products, Inc. | UTMD | $207M | 19.24 | 1.74 | 9.5% | 7.91 |
| OraSure Technologies, Inc. | OSUR | $205M | - | 0.61 | -20.2% | -0.32 |
| Atrium Therapeutics, Inc. | RNA | $202M | - | -3.21 | -37.0% | - |
| OmniAb, Inc. | OABI | $197M | - | 0.74 | -24.3% | -3.48 |
| Peer Median | - | 19.24 | 0.92 | -22.2% | -0.46 | |